Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers

被引:25
|
作者
Fujimoto, Yukie [1 ]
Watanabe, Takahiro [2 ]
Hida, Akira I. [3 ]
Higuchi, Tomoko [1 ]
Miyagawa, Yoshimasa [1 ]
Ozawa, Hiromi [1 ]
Bun, Ayako [1 ]
Fukui, Reiko [1 ]
Sata, Atsushi [1 ]
Imamura, Michiko [1 ]
Hirota, Seiichi [2 ]
Miyoshi, Yasuo [1 ]
机构
[1] Hyogo Coll Med, Dept Surg, Div Breast & Endocrine Surg, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Dept Surg Pathol, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[3] Matsuyama Shimin Hosp, Dept Pathol, 2-6-5 Otemachi, Matsuyama, Ehime 7900067, Japan
关键词
Breast cancer; Tumor-infiltrating lymphocytes; Ki67; Prognosis; INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; HIGHLIGHTS; CHEMOTHERAPY; SUBTYPES;
D O I
10.1007/s12282-019-00977-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been established in breast cancers with estrogen receptor (ER)-negative and human epithelial growth factor receptor 2 (HER2)-negative or HER2-positive subtypes; however, its utility concerning the ER + /HER2-subtype remains unclear. Methods We evaluated the prognostic value of TILs by analyzing 717 invasive breast cancer operation cases. TILs were classified into three groups based on the proportion of area within the tumor: low (< 10%), intermediate (10-50%), and high (> 50%). Disease-free survival (DFS) and overall survival (OS) were calculated according to TIL levels. Results Although there was no significant association between TIL levels and DFS or OS in all patients, high TILs were significantly associated with favorable DFS in Ki67-high (n = 238, p = 0.035) but not in Ki67-low (n = 470, p = 0.46) breast cancers. Multivariable analysis showed that high TILs were a significant and independent factor for DFS (HR 0.34; 95% CI 0.10-0.87; p = 0.023) among the Ki67-high group. In the ER + /HER2 - subtype, high-TILs showed favorable DFS in the Ki67-high group, although this was not statistically significant (p = 0.48); in contrast, unfavorable DFS was observed in the Ki67-low group (p = 0.027). Conclusions In Ki67-high breast cancers, high TILs were associated with favorable DFS, irrespective of subtype, but increasing TIL levels correlated with worse DFS in the Ki67-low group with the ER + /HER2 -subtype. These results highlight variation in TIL prognostic significance between Ki67-high and -low breast cancers, particularly for the ER + /HER2 - subtype.
引用
收藏
页码:738 / 747
页数:10
相关论文
共 50 条
  • [1] Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers
    Yukie Fujimoto
    Takahiro Watanabe
    Akira I. Hida
    Tomoko Higuchi
    Yoshimasa Miyagawa
    Hiromi Ozawa
    Ayako Bun
    Reiko Fukui
    Atsushi Sata
    Michiko Imamura
    Seiichi Hirota
    Yasuo Miyoshi
    Breast Cancer, 2019, 26 : 738 - 747
  • [2] Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers
    Tomoko Yagi
    Natsuko Inoue
    Ayako Yanai
    Keiko Murase
    Michiko Imamura
    Yoshimasa Miyagawa
    Yukie Enomoto
    Arisa Nishimukai
    Yuichi Takatsuka
    Seiichi Hirota
    Kouhei Akazawa
    Yasuo Miyoshi
    Breast Cancer, 2016, 23 : 224 - 230
  • [3] Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers
    Yagi, Tomoko
    Inoue, Natsuko
    Yanai, Ayako
    Murase, Keiko
    Imamura, Michiko
    Miyagawa, Yoshimasa
    Enomoto, Yukie
    Nishimukai, Arisa
    Takatsuka, Yuichi
    Hirota, Seiichi
    Akazawa, Kouhei
    Miyoshi, Yasuo
    BREAST CANCER, 2016, 23 (02) : 224 - 230
  • [4] Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer
    Zilenaite-Petrulaitiene, Dovile
    Rasmusson, Allan
    Besusparis, Justinas
    Valkiuniene, Ruta Barbora
    Augulis, Renaldas
    Laurinaviciene, Aida
    Plancoulaine, Benoit
    Petkevicius, Linas
    Laurinavicius, Arvydas
    VIRCHOWS ARCHIV, 2025, 486 (02) : 287 - 298
  • [5] Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
    Rossi, L.
    Laas, E.
    Mallon, P.
    Vincent-Salomon, A.
    Guinebretiere, J-M
    Lerebours, F.
    Rouzier, R.
    Pierga, J-Y
    Reyal, F.
    BRITISH JOURNAL OF CANCER, 2015, 113 (07) : 996 - 1002
  • [6] Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
    L Rossi
    E Laas
    P Mallon
    A Vincent-Salomon
    J-M Guinebretiere
    F Lerebours
    R Rouzier
    J-Y Pierga
    F Reyal
    British Journal of Cancer, 2015, 113 : 996 - 1002
  • [7] Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer
    Kang, Young-Joon
    Lee, Han-Byoel
    Kim, Yun Gyoung
    Han, JaiHong
    Kim, Yumi
    Yoo, Tae-Kyung
    Lee, Eun-Shin
    Moon, Hyeong-Gon
    Noh, Dong-Young
    Han, Wonshik
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [8] An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers
    Reiko Fukui
    Takahiro Watanabe
    Koji Morimoto
    Yukie Fujimoto
    Masayuki Nagahashi
    Eri Ishikawa
    Seiichi Hirota
    Yasuo Miyoshi
    Breast Cancer, 2023, 30 : 703 - 713
  • [9] An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers
    Fukui, Reiko
    Watanabe, Takahiro
    Morimoto, Koji
    Fujimoto, Yukie
    Nagahashi, Masayuki
    Ishikawa, Eri
    Hirota, Seiichi
    Miyoshi, Yasuo
    BREAST CANCER, 2023, 30 (05) : 703 - 713
  • [10] Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer
    Tozuka, Katsunori
    Horiguchi, Jun
    Takata, Daisuke
    Rokutanda, Nana
    Nagaoka, Rin
    Tokiniwa, Hideaki
    Kikuchi, Mami
    Satou, Ayako
    Takei, Hiroyuki
    Takeyoshi, Izumi
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (01) : 93 - 99